nodes	percent_of_prediction	percent_of_DWPC	metapath
Remifentanil—OPRM1—nicotine dependence	0.889	1	CbGaD
Remifentanil—Respiratory tract congestion—Varenicline—nicotine dependence	0.00631	0.064	CcSEcCtD
Remifentanil—Musculoskeletal chest pain—Varenicline—nicotine dependence	0.00594	0.0602	CcSEcCtD
Remifentanil—Haematochezia—Varenicline—nicotine dependence	0.00571	0.0579	CcSEcCtD
Remifentanil—Dysphoria—Varenicline—nicotine dependence	0.00532	0.054	CcSEcCtD
Remifentanil—Nystagmus—Varenicline—nicotine dependence	0.00322	0.0327	CcSEcCtD
Remifentanil—Rhinorrhoea—Varenicline—nicotine dependence	0.00284	0.0288	CcSEcCtD
Remifentanil—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.00255	0.0258	CcSEcCtD
Remifentanil—Ventricular extrasystoles—Varenicline—nicotine dependence	0.00255	0.0258	CcSEcCtD
Remifentanil—Leukocytosis—Varenicline—nicotine dependence	0.00245	0.0248	CcSEcCtD
Remifentanil—Anileridine—OPRM1—nicotine dependence	0.00233	0.289	CrCbGaD
Remifentanil—Hyperkalaemia—Varenicline—nicotine dependence	0.00226	0.0229	CcSEcCtD
Remifentanil—Nightmare—Varenicline—nicotine dependence	0.00222	0.0225	CcSEcCtD
Remifentanil—Sufentanil—OPRM1—nicotine dependence	0.00213	0.264	CrCbGaD
Remifentanil—Alfentanil—OPRM1—nicotine dependence	0.00198	0.246	CrCbGaD
Remifentanil—Sleep disorder—Varenicline—nicotine dependence	0.00193	0.0196	CcSEcCtD
Remifentanil—Disorientation—Varenicline—nicotine dependence	0.00187	0.0189	CcSEcCtD
Remifentanil—Amnesia—Varenicline—nicotine dependence	0.00178	0.018	CcSEcCtD
Remifentanil—Visual disturbance—Varenicline—nicotine dependence	0.00176	0.0179	CcSEcCtD
Remifentanil—Atrial fibrillation—Varenicline—nicotine dependence	0.00176	0.0179	CcSEcCtD
Remifentanil—Urinary retention—Varenicline—nicotine dependence	0.00159	0.0161	CcSEcCtD
Remifentanil—Hypokalaemia—Varenicline—nicotine dependence	0.00152	0.0154	CcSEcCtD
Remifentanil—Nasopharyngitis—Varenicline—nicotine dependence	0.00149	0.0152	CcSEcCtD
Remifentanil—Dysphagia—Varenicline—nicotine dependence	0.00144	0.0146	CcSEcCtD
Remifentanil—Bronchitis—Varenicline—nicotine dependence	0.00139	0.0141	CcSEcCtD
Remifentanil—Abdominal discomfort—Varenicline—nicotine dependence	0.00138	0.014	CcSEcCtD
Remifentanil—Hyperglycaemia—Varenicline—nicotine dependence	0.0013	0.0132	CcSEcCtD
Remifentanil—Bradycardia—Varenicline—nicotine dependence	0.00118	0.0119	CcSEcCtD
Remifentanil—Hallucination—Varenicline—nicotine dependence	0.00115	0.0117	CcSEcCtD
Remifentanil—Visual impairment—Varenicline—nicotine dependence	0.00111	0.0113	CcSEcCtD
Remifentanil—Cardiac disorder—Varenicline—nicotine dependence	0.00107	0.0109	CcSEcCtD
Remifentanil—Angiopathy—Varenicline—nicotine dependence	0.00105	0.0106	CcSEcCtD
Remifentanil—Immune system disorder—Varenicline—nicotine dependence	0.00104	0.0106	CcSEcCtD
Remifentanil—Mediastinal disorder—Varenicline—nicotine dependence	0.00104	0.0106	CcSEcCtD
Remifentanil—Chills—Varenicline—nicotine dependence	0.00104	0.0105	CcSEcCtD
Remifentanil—Arrhythmia—Varenicline—nicotine dependence	0.00103	0.0105	CcSEcCtD
Remifentanil—Erythema—Varenicline—nicotine dependence	0.00101	0.0102	CcSEcCtD
Remifentanil—Tremor—Varenicline—nicotine dependence	0.000943	0.00956	CcSEcCtD
Remifentanil—Anaemia—Varenicline—nicotine dependence	0.00093	0.00943	CcSEcCtD
Remifentanil—Agitation—Varenicline—nicotine dependence	0.000925	0.00938	CcSEcCtD
Remifentanil—Syncope—Varenicline—nicotine dependence	0.000902	0.00915	CcSEcCtD
Remifentanil—Pethidine—OPRM1—nicotine dependence	0.000893	0.111	CrCbGaD
Remifentanil—Loss of consciousness—Varenicline—nicotine dependence	0.000884	0.00897	CcSEcCtD
Remifentanil—Cough—Varenicline—nicotine dependence	0.000878	0.0089	CcSEcCtD
Remifentanil—Convulsion—Varenicline—nicotine dependence	0.000872	0.00884	CcSEcCtD
Remifentanil—Hypertension—Varenicline—nicotine dependence	0.000869	0.00881	CcSEcCtD
Remifentanil—Anxiety—Varenicline—nicotine dependence	0.000854	0.00866	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.000851	0.00863	CcSEcCtD
Remifentanil—Dry mouth—Varenicline—nicotine dependence	0.000838	0.0085	CcSEcCtD
Remifentanil—Oedema—Varenicline—nicotine dependence	0.000821	0.00833	CcSEcCtD
Remifentanil—Shock—Varenicline—nicotine dependence	0.000808	0.00819	CcSEcCtD
Remifentanil—Nervous system disorder—Varenicline—nicotine dependence	0.000805	0.00817	CcSEcCtD
Remifentanil—Thrombocytopenia—Varenicline—nicotine dependence	0.000804	0.00815	CcSEcCtD
Remifentanil—Tachycardia—Varenicline—nicotine dependence	0.000802	0.00813	CcSEcCtD
Remifentanil—Skin disorder—Varenicline—nicotine dependence	0.000798	0.00809	CcSEcCtD
Remifentanil—Hyperhidrosis—Varenicline—nicotine dependence	0.000794	0.00805	CcSEcCtD
Remifentanil—Hypotension—Varenicline—nicotine dependence	0.000767	0.00778	CcSEcCtD
Remifentanil—Dyspnoea—Varenicline—nicotine dependence	0.000732	0.00742	CcSEcCtD
Remifentanil—Somnolence—Varenicline—nicotine dependence	0.00073	0.0074	CcSEcCtD
Remifentanil—Fentanyl—OPRM1—nicotine dependence	0.000726	0.09	CrCbGaD
Remifentanil—Dyspepsia—Varenicline—nicotine dependence	0.000723	0.00733	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000709	0.00719	CcSEcCtD
Remifentanil—Pain—Varenicline—nicotine dependence	0.000702	0.00712	CcSEcCtD
Remifentanil—Constipation—Varenicline—nicotine dependence	0.000702	0.00712	CcSEcCtD
Remifentanil—Feeling abnormal—Varenicline—nicotine dependence	0.000677	0.00686	CcSEcCtD
Remifentanil—Urticaria—Varenicline—nicotine dependence	0.000652	0.00662	CcSEcCtD
Remifentanil—Body temperature increased—Varenicline—nicotine dependence	0.000649	0.00658	CcSEcCtD
Remifentanil—Hypersensitivity—Varenicline—nicotine dependence	0.000605	0.00614	CcSEcCtD
Remifentanil—Pruritus—Varenicline—nicotine dependence	0.000581	0.00589	CcSEcCtD
Remifentanil—Diarrhoea—Varenicline—nicotine dependence	0.000562	0.0057	CcSEcCtD
Remifentanil—Dizziness—Varenicline—nicotine dependence	0.000543	0.00551	CcSEcCtD
Remifentanil—Vomiting—Varenicline—nicotine dependence	0.000522	0.00529	CcSEcCtD
Remifentanil—Rash—Varenicline—nicotine dependence	0.000518	0.00525	CcSEcCtD
Remifentanil—Dermatitis—Varenicline—nicotine dependence	0.000517	0.00525	CcSEcCtD
Remifentanil—Headache—Varenicline—nicotine dependence	0.000514	0.00522	CcSEcCtD
Remifentanil—Nausea—Varenicline—nicotine dependence	0.000488	0.00495	CcSEcCtD
Remifentanil—OPRD1—Peptide GPCRs—OPRM1—nicotine dependence	0.000224	0.0576	CbGpPWpGaD
Remifentanil—OPRD1—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000211	0.0542	CbGpPWpGaD
Remifentanil—OPRK1—Peptide GPCRs—OPRM1—nicotine dependence	0.000196	0.0505	CbGpPWpGaD
Remifentanil—OPRK1—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000185	0.0475	CbGpPWpGaD
Remifentanil—OPRM1—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000156	0.0402	CbGpPWpGaD
Remifentanil—OPRD1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000128	0.0328	CbGpPWpGaD
Remifentanil—OPRK1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000112	0.0288	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.000105	0.0271	CbGpPWpGaD
Remifentanil—OPRM1—GPCR ligand binding—TAS2R16—nicotine dependence	9.45e-05	0.0243	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	9.23e-05	0.0237	CbGpPWpGaD
Remifentanil—OPRD1—G alpha (i) signalling events—OPRM1—nicotine dependence	8.88e-05	0.0228	CbGpPWpGaD
Remifentanil—OPRD1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	8.24e-05	0.0212	CbGpPWpGaD
Remifentanil—OPRK1—G alpha (i) signalling events—OPRM1—nicotine dependence	7.79e-05	0.02	CbGpPWpGaD
Remifentanil—OPRK1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	7.23e-05	0.0186	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—TAS2R16—nicotine dependence	7.21e-05	0.0185	CbGpPWpGaD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	7.06e-05	0.0182	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—TAS2R16—nicotine dependence	6.55e-05	0.0168	CbGpPWpGaD
Remifentanil—OPRD1—G alpha (i) signalling events—DRD2—nicotine dependence	6.42e-05	0.0165	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—TAS2R16—nicotine dependence	6.32e-05	0.0163	CbGpPWpGaD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	6.19e-05	0.0159	CbGpPWpGaD
Remifentanil—OPRD1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	5.96e-05	0.0153	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—TAS2R16—nicotine dependence	5.74e-05	0.0148	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—FGD1—nicotine dependence	5.66e-05	0.0145	CbGpPWpGaD
Remifentanil—OPRK1—G alpha (i) signalling events—DRD2—nicotine dependence	5.63e-05	0.0145	CbGpPWpGaD
Remifentanil—OPRD1—GPCR ligand binding—OPRM1—nicotine dependence	5.38e-05	0.0138	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	5.34e-05	0.0137	CbGpPWpGaD
Remifentanil—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	5.23e-05	0.0134	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—FGD1—nicotine dependence	5.14e-05	0.0132	CbGpPWpGaD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	5.11e-05	0.0131	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—FGD1—nicotine dependence	4.96e-05	0.0128	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—TAS2R16—nicotine dependence	4.85e-05	0.0125	CbGpPWpGaD
Remifentanil—OPRM1—G alpha (i) signalling events—DRD2—nicotine dependence	4.76e-05	0.0122	CbGpPWpGaD
Remifentanil—OPRK1—GPCR ligand binding—OPRM1—nicotine dependence	4.72e-05	0.0121	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—FGD1—nicotine dependence	4.5e-05	0.0116	CbGpPWpGaD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	4.48e-05	0.0115	CbGpPWpGaD
Remifentanil—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	4.42e-05	0.0114	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—FGD1—nicotine dependence	4.19e-05	0.0108	CbGpPWpGaD
Remifentanil—OPRD1—GPCR ligand binding—DRD2—nicotine dependence	3.89e-05	0.01	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—TAS2R16—nicotine dependence	3.87e-05	0.00994	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—FGD1—nicotine dependence	3.81e-05	0.00979	CbGpPWpGaD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	3.78e-05	0.00973	CbGpPWpGaD
Remifentanil—OPRK1—GPCR ligand binding—DRD2—nicotine dependence	3.41e-05	0.00877	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—TAS2R16—nicotine dependence	3.39e-05	0.00872	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—OPRM1—nicotine dependence	3.04e-05	0.00781	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—FGD1—nicotine dependence	3.03e-05	0.0078	CbGpPWpGaD
Remifentanil—OPRM1—GPCR ligand binding—DRD2—nicotine dependence	2.88e-05	0.00741	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—TAS2R16—nicotine dependence	2.87e-05	0.00737	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—OPRM1—nicotine dependence	2.76e-05	0.0071	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—AKR1B10—nicotine dependence	2.68e-05	0.00689	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—OPRM1—nicotine dependence	2.66e-05	0.00685	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—FGD1—nicotine dependence	2.66e-05	0.00684	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—OPRM1—nicotine dependence	2.42e-05	0.00622	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—AKR1B10—nicotine dependence	2.35e-05	0.00604	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—FGD1—nicotine dependence	2.25e-05	0.00578	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—DRD2—nicotine dependence	2.2e-05	0.00565	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—DRD2—nicotine dependence	2e-05	0.00513	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—AKR1B10—nicotine dependence	1.99e-05	0.00511	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—DRD2—nicotine dependence	1.93e-05	0.00495	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—WASF2—nicotine dependence	1.89e-05	0.00486	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—WASF1—nicotine dependence	1.81e-05	0.00466	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—DRD2—nicotine dependence	1.75e-05	0.0045	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—WASF2—nicotine dependence	1.66e-05	0.00426	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—OPRM1—nicotine dependence	1.63e-05	0.00419	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—DRD2—nicotine dependence	1.63e-05	0.00419	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—WASF1—nicotine dependence	1.59e-05	0.00408	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—DRD2—nicotine dependence	1.48e-05	0.0038	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—OPRM1—nicotine dependence	1.43e-05	0.00368	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—WASF2—nicotine dependence	1.4e-05	0.0036	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—WASF1—nicotine dependence	1.34e-05	0.00345	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—DRD2—nicotine dependence	1.18e-05	0.00303	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—DRD2—nicotine dependence	1.03e-05	0.00266	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—DRD2—nicotine dependence	8.73e-06	0.00225	CbGpPWpGaD
